WY-14643 attenuates lipid deposition via activation of the PPARα/CPT1A axis by targeting Gly335 to inhibit cell proliferation and migration in ccRCC

Background: Histologically, cytoplasmic deposits of lipids and glycogen are common in clear cell renal cell carcinoma (ccRCC). Owing to the significance of lipid deposition in ccRCC, numerous trials targeting lipid metabolism have shown certain therapeutic potential. The agonism of peroxisome proliferator-activated receptor-alpha (PPAR alpha) via ligands, including WY-14,643, has been considered a promising intervention for cancers. Methods: First, the effects of WY-14,643 on malignant behaviors were investigated in ccRCC in vitro. After RNA sequencing, the changes in lipid metabolism, especially neutral lipids and glycerol, were further evaluated. Finally, the underlying mechanisms were revealed. Results: Phenotypically, the proliferation and migration of ccRCC cells treated with WY-14,643 were significantly inhibited in vitro. A theoretical functional mechanism was proposed in ccRCC: WY-14,643 mediates lipid consumption by recognizing carnitine palmitoyltransferase 1 A (CPT1A). Activation of PPAR alpha using WY-14,643 reduces lipid deposition by increasing the CPT1A level, which also suppresses the NF-kappa B signaling pathway. Spatially, WY-14,643 binds and activates PPAR alpha by targeting Gly335. Conclusion: Overall, WY-14,643 suppresses the biological behaviors of ccRCC in terms of cell proliferation, migration, and cell cycle arrest. Furthermore, its anticancer properties are mediated by the inhibition of lipid accumulation, at least in part, through the PPAR alpha/CPT1A axis by targeting Gly335, as part of the process, NF-kappa B signaling is also suppressed. Pharmacological activation of PPAR alpha might offer a new treatment option for ccRCC.

Automated summary

The findings suggest that WY-14,643 inhibits the malignant behaviors of ccRCC by modulating lipid metabolism and targeting the PPAR alpha/CPT1A axis.